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Abstract: In eukaryotes, mature mRNA is formed through 
modifications of precursor mRNA, one of which is 5′ cap biosynthesis, 
involving RNA cap guanine-N7 methyltransferase (N7-MTase). N7-
MTases are also encoded by some eukaryotic viruses and facilitate 
their replication. N7-MTase inhibitors have therapeutic potential, but 
their discovery is difficult because long RNA substrates are usually 
required for activity. Herein, we report a universal N7-MTase activity 
assay based on small-molecule fluorescent probes. We synthesized 
12 fluorescent substrate analogs (GpppA and GpppG derivatives) 
varying in the dye type, dye attachment site, and linker length. GpppA 
labeled with pyrene at the 3′-O position of adenosine acted as an 
artificial substrate with properties of a turn-off probe for all three tested 
N7-MTases (human, parasite, and viral). Using this compound, a N7-
MTase inhibitor assay adaptable to high-throughput screening was 
developed and used for screening of synthetic substrate analogs and 
a commercial library. Several inhibitors with nanomolar activities were 
identified. 
Introduction 
In eukaryotic cells, before a newly synthesized mRNA is 
translated into the protein, it undergoes a series of modifications 
(mRNA maturation), occurring both co- and post-transcriptionally. 
One step of mRNA maturation involves the addition of a so-called 
cap structure at the 5′ end. The cap is composed of a positively 
charged nucleobase, N7-methylguanosine, and a negatively 
charged 5′,5′-triphosphate bridge, which are involved in 
interactions with specific proteins and regulate many crucial 
processes, including translation initiation and mRNA transport 
and turnover.[1] 
The biosynthesis of the cap engages three enzymes. First, 
RNA 5′-triphosphatase (TPase) hydrolyzes the bond between β- 
and γ-phosphates of the RNA 5′-triphosphate. Then, 
guanylyltransferase (GTase) transfers the GMP moiety from GTP 
to the RNA 5′ end to produce GpppRNA.[2] The final step is the 
methylation of the guanosine at the N7 position by mRNA cap 
guanine-N7 methyltransferase (N7-MTase), which transfers the 
methyl group from S-adenosyl-ʟ-methionine (SAM) to Gppp-
capped RNA and releases S-adenosyl-ʟ-homocysteine (SAH) as 
a byproduct. This mechanism is conserved in all eukaryotic 
organisms and involves nucleophilic substitution with SAM, as an 
electrophile, providing the methyl group for the nucleotide N7 
position, a nucleophile.[3] The catalytic mechanism requires the 
approximation of the substrate and a proper orientation of the cap 
N7-nucleophile toward S-CH3.[4] 
In mammals, the first two capping steps are catalyzed by a 
bifunctional capping enzyme (CE), which possesses the activity 
of both TPase and GTase.[5] Human mRNA cap N7-MTase 
(RNMT) is a nuclear protein consisting of a catalytic domain and 
N-terminal domain.[6] The latter is not required for catalytic activity 
but is responsible for binding of the RNMT-activating miniprotein 
(RAM), which stabilizes the catalytically optimal RNMT 
structure.[7] Reduced RNMT activity has been recently reported to 
inhibit the proliferation and to increase the apoptosis of breast 
cancer cells.[8] Hence, RNMT-RAM is a promising target for anti-
cancer therapy. 
Eukaryotic viruses also cap their mRNAs to mask them from 
the innate immune system and increase the expression of 
pathogenic proteins.[9] Some viruses (e.g., adenovirus and 
herpesvirus) are dependent on host enzymes to cap their 
mRNAs,[3, 10] while others encode their own proteins to cap 
mRNA.[11] The latter utilize capping mechanisms that are either 
analogous to eukaryotic mRNA capping or rely on mechanistically 
distinct pathways.[12] For instance, in alphaviruses, N7-MTase 
transfers the methyl group directly to the GTP molecule, and the 
resultant m7GTP is incorporated into the 5′ end of mRNA,[11] 
whereas non-segmented negative-sense viruses incorporate 
GDP instead of GMP during cap biosynthesis.[13] Poxviruses 
(including vaccinia virus and African swine fever virus) encode 
trifunctional mRNA CEs, which possess all three activities 
(TPase, GTase, and N7-MTase).[12, 14] The vaccinia CE (VCE) is 
a heterodimeric protein consisting of two subunits, D1, which is 
responsible for the activity, and D12, stimulating substrate binding 
by D1.[15] Coronaviruses (CoVs) also utilize their own capping 
mechanism, which is still not fully understood but presumably 
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Nonstructural protein NS14 has been identified to have an N7-
MTase activity in the severe acute respiratory syndrome CoV.[17] 
The reliance on their own enzymatic apparatus to cap mRNA 
makes viral N7-MTases potential targets for the treatment of 
many viral infections. In flaviviruses (e.g., dengue, West Nile, and 
Zika viruses), widely known for their pathogenic effects, NS5 RNA 
MTases are necessary for virus replication and have already been 
tested as potential drug targets.[18, 19]  
N7-MTases are also considered drug targets in parasite 
infections.[20] Ecm1 from Encephalitozoon cuniculi is one of the 
best characterized parasitic N7-MTases and also the smallest 
known N7-MTase, thus being often used as a model protein.[21] 
Ecm1 is also known for its ability to transfer groups larger than 
methyl, allowing for the modification of the cap N7 position with, 
e.g., bioorthogonal functional groups such as allyl, alkyne, or 
azide, which can be further used for fluorescent labeling and 
mRNA imaging within the cell.[22] 
Because of the significant therapeutic potential of N7-
MTases, finding new potent and selective N7-MTase inhibitors is 
of great interest. Several SAM and SAH analogs (e.g., the 
naturally occurring nucleoside sinefungin) have been reported to 
inhibit the activity of various N7-MTases.[23, 24] However, targeting 
the SAM-binding pocket is non-specific and increases toxicity.[25] 
Designing inhibitors targeting the RNA cap-binding site in N7-
MTases could afford more specific inhibition. Some nucleotide-
like inhibitors, based on the exploration of specific features of the 
N7-MTase binding pocket, have already been reported.[26, 27] In 
order to find new N7-MTase inhibitors, cost-effective methods, 
suitable for high-throughput experiments, are required. However, 
designing N7-methylation assays is demanding, as the natural 
substrate for most N7-MTases is GpppRNA, the large-scale 
synthesis of which is challenging.[28] To overcome this problem, 
ligation of two shorter RNA fragments has been proposed.[29] 
Other approaches to the discovery N7-MTase inhibitors employ 
radiolabeled substrates, such as [methyl-3H]-SAM[26, 28] or [32P]-
labeled GpppA-RNA.[19] However, the disadvantages of these 
methods are the use of radioactivity and the necessity to separate 
substrates and products by thin layer chromatography. Other 
methods include fragment-based X-ray crystallographic 
screening[30] and whole-cell yeast-based screening.[31, 32] A 
competitive fluorescent immunoassay, based on fluorescence 
polarization and using a SAH antibody, has also been reported,[33] 
and BODIPY-labeled GTP was applied in a fluorescence 
polarization assay to identify dengue virus MTase inhibitors 
targeting the GTP-binding site.[34] A time-Resolved Fluorescence 
method for studies on SARS-nsp14 enzyme has also been 
developed.[35] 
All of these methods provided insights into the N7-MTase 
activity and inhibition. However, to the best of our knowledge, 
there is no direct method allowing to monitor N7-MTase activity in 
real-time using small molecular probes. In this study, we sought 
to develop a fluorescent assay for direct monitoring of mRNA cap 
N7-MTase activity that relies on structurally simple substrates and 
is adaptable to HTS inhibitor discovery. To this end, we used three 
model N7-MTases, a human RNMT-RAM, the parasite Ecm1 
enzyme, and VCE. The methodology was initially optimized for 
Ecm1 and then adopted to RNMT-RAM and VCE. Since our 
preliminary experiments indicated that a dinucleotide is a minimal 
substrate for efficient catalysis (Figure S1),[23] we focused on 
fluorescently labeled GpppA and GpppG analogs as potential 
substrates that represent a reasonable compromise between the 
structural complexity and requirements of the enzyme. We aimed 
to identify probes that change emission properties upon N7-
methylation (Figure 1) and screen various fluorescent tags, 
followed by the optimization of the position and type of the dye 
attached (linker length) for the best hit. The optimized structure 
was then used to demonstrate its utility for the development of 
HTS inhibitor discovery assay based on direct fluorescence 
intensity (FLINT) measurements.  
 




To select the most suitable fluorescent dye for probe 
development, we synthesized a set of alkyne-functionalized 
precursors (compounds 1-5) which were subsequently converted 
into various fluorescent probes (compounds 6–10). We began 
with the synthesis of seven GpppA derivatives functionalized at 
the adenosine moiety (compounds 6a–g; Figure 2). To this end, 
a GpppA analog equipped with an alkyne handle (1) was 
synthesized in a few steps, starting from an appropriate ADP 
precursor functionalized with propargylamine at the 3′-O position 
(Figure S2). P-imidazolide of (N-propargyl)-3′-
carbamoyloadenosine diphosphate[36] was coupled with the 
triethylammonium salt of GMP in DMF, with MgCl2 as a reaction 
mediator, to give 1, which was purified by semipreparative RP-
HPLC in 41% yield. Compound 1 was transformed into 
fluorescently labeled probes 6a–g in CuAAC reactions with azide-
functionalized fluorescent dyes (Figure 2A). The reactions were 
carried out in a DMSO/H2O solution (ratio dependent on the 
fluorescent tag solubility) under standard catalytic conditions 
(copper [II] sulfate/sodium-ʟ-ascorbate mixture). To quench the 
reactions, an aqueous solution of ethylenediaminetetraacetic acid 
disodium salt was added. The probes were purified using 
analytical or semipreparative HPLC (Table S1). The other alkyne-
functionalized GpppA and GpppG analogs (2–4) and 
corresponding probes (7–9) were synthesized using a similar 
approach and previously reported functionalization strategies 
(Figure S2A,B).[36, 37] Additionally, the product analog 5 was 
synthesized via N7-methylation of compound 1 and functionalized 
to yield probes 10a,b (Figure S2C). The structures of the 
fluorescent nucleotides were confirmed by HRMS. For non-
fluorescent precursors, 1H, 31P, and 1H-1H COSY NMR spectra 
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Overall, a set of 12 fluorescently labeled nucleotides was 
synthesized (Figure 2B). Different fluorescent dyes were tested 
for labeling at the adenosine 3′-O position, including pyrene (Py, 
6a; Py3, 6b), perylene (Pe, 6c), boron dipyrromethene analog 
(BDP-FL, 6d), 5-carboxyfluorescein (5-FAM, 6e), cyanine 3 (Cy3, 
6f), and cyanine 5 (Cy5, 6g) (Figure 2C). Different Py-labeling 
positions were also explored, including the 2′-O/3′-O positions of 
guanosine (7), N6 position of adenosine (8), and N1 position of 
guanosine (9). The effect of linker elongation was also explored 
for one probe (6b). 
 
Figure 2. A) Synthesis of fluorescently labelled dinucleotide cap analogs. B) 
Structures of the fluorescent probes synthesized in this work. C) Structures of 
tested dyes. 
Preliminary Spectroscopic and Enzymatic Studies 
We next characterized the spectroscopic properties of GpppA-
derived fluorescent probes 6a–g by registering their absorption, 
fluorescence excitation, and emission spectra. For all the 
compounds, the spectral shape and absorption maxima were 
analogous to those of isolated fluorescent tags (Figure S3, Table 
1). The Py-modified probe 6a showed only monomer emission at 
the studied concentrations (<10 µM).  
Subsequently, we subjected probes 6a–g to enzymatic N7-
methylation using Ecm1 as a model enzyme to identify those that 
could act as FLINT probes. Each probe was incubated with Ecm1 
(10 nM) in the presence of excess SAM (Figure 3A), and FLINT 
was measured time dependently at the dye emission maximum. 
To quantify FLINT changes, a quenching factor (Q) was 
determined for each probe as the ratio of FLINT before and after 
complete N7-methylation. If Q was <1, the compound was a turn-
on FLINT probe; if Q was >1, the compound was a turn-off FLINT 
probe; and if Q was ~1, the compound was not a FLINT probe, 
which could result from either an absence of fluorescence 
changes or the lack of the enzymatic reaction. Among all the 
studied probes, only a Py-labeled probe (6a) showed a Q value 
>1 (~1.5; Table 1). This result indicated that the fluorescence of 
Py was stronger quenched by interactions with an N7-methylated 
(product) than non-methylated (substrate) guanosine. Hence, we 
selected Py as the most suitable label and focused on maximizing 
the response. We evaluated a series of ribose and nucleobase 
functionalized dinucleotides, such as Py-labeled GpppN at the 2′-
O/3′-O position of guanosine (7), N6 position of adenine (8), and 
N1 position of the second guanine in GpppG (9). For each probe, 
we determined Q and found that only probe 6a notably changed 
its FLINT upon incubation with SAM and Ecm1 (Figure 3B).
Table 1. Spectral properties of fluorescently labeled GpppA and GpppG analogs.[a] 
Compound abbreviation (number) Absorption λmax (nm) Emission λmax (nm) QY (%) QEcm1 (-) 
Gp3A-3′-O-Py (6a) 330, 345 378, 398 12.3 ± 0.3 1.5 
Gp3A-3′-O-Py3 (6b) 330, 345 378, 398 29.8 ± 0.5 3.4 
Gp3A-3′-O-Pe (6c) 418, 443 493 99.8 ± 0.9 1.0 
Gp3A-3’-O-BDP-FL (6d) 505 513 54.8 ± 0.1 1.0 
Gp3A-3′-O-5-FAM (6e) 498 528 44.7 ± 0.3 1.0 
Gp3A-3′-O-Cy3 (6f) 545 563 49.2 ± 0.1 1.1 
Gp3A-3′-O-Cy5 (6g) 642 660 22.6 ± 0.9 1.1. 
2′-O/3′-O-Py-Gp3A (7) 330, 345 378, 398 11.4 ± 0.3 1.1 
Gp3A(N6)-Py (8) 330, 345 378, 398 14.9 ± 0.4 1.1 
Gp3G(N1)-Py (9) 330, 345 378, 398 3.9 ± 0.1 1.1 
m7Gp3A-3′-O-Py (10a) 330, 345 378, 398 6.57 ± 0.03 Product[b] 
m7Gp3A-3′-O-Py3 (10b) 330, 345 378, 398 4.01 ± 0.02 Product[b] 
[a] Data are the means ± SD of three independent experiments. [b] Obtained by chemical synthesis. QEcm1 (-) – quenching factor for N7-methylation reaction by Ecm1. 
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Figure 3. Structural optimization of fluorescent probes for N7-MTases by 
measuring fluorescence intensity changes at the emission maximum during 
incubation of different probes with Ecm1: A) Gp3A analogs labeled with the 
indicated fluorescence tags at the adenosine ribose moiety (2 µM), 50 µM SAM 
and Ecm1 (10 nM); B) Py-labeled Gp3A functionalized at different positions: 
adenosine ribose (6a), guanosine ribose (7a), and the N6 position of adenine 
(8) or Gp3G functionalized at the N1 position (9) (2 µM), SAM (50 µM) and Ecm1 
(10 nM); C) Py-labeled Gp3A analogs differing in the length of the linker between 
Py and the cap moiety (2 µM), SAM (50 µM) and Ecm1 (10 nM); D) Emission 
spectra registered at 1-minute intervals during incubation of probe 6b (2 µM) 
with SAM (50 µM) and the Ecm1 enzyme (10 nM). 
Probes 7, 8, and 9 showed virtually no changes in 
fluorescence (Figure 3B), although all of them were N7-
methylated to some extent, as independently determined using 
HPLC-MS (Figure S4). Finally, we tested the influence of the 
length of the linker connecting Py and the 3′-O position of 
adenosine ribose and found that a longer linker (Py3, 6b) led to a 
more than twofold increase in the response upon N7-methylation 
compared to probe 6a (Figure 3C). 
To additionally confirm our observations that FLINT values of 
probes 6a and 6b decreased over time as a result of enzymatic 
N7-methylation, we synthesized two N7-methylated fluorescent 
probes (10a and 10b) and determined their quantum yields (QYs; 
Table 1) using a comparative method.[38] QYs of m7GpppA-
derived probes were two to seven times lower than those of their 
non-methylated forms. This finding also indicated that the largest 
difference between the substrate and the product of the enzymatic 
N7-methylation reaction could be expected for probe 6b (QY: 
29.8% versus 4.0% for 10b).  
Eventually, we selected 6b as the most suitable fluorescent 
probe for the development of a FLINT assay.  
Development of an Activity Assay 
To optimize the N7-MTase assay conditions, we characterized 
steady-state parameters for the methylation of probe 6b by Ecm1 
and RNMT-RAM. To this end, probe 6b was incubated at 
concentrations of 0–15 µM with SAM as a cosubstrate (50 µM for 
Ecm1 or 20 µM for RNMT-RAM) and the enzymes (10 nM Ecm1, 
20 nM RNMT-RAM) at 30 °C, and FLINT was measured over 
time. We did not include SAH degrading enzymes in the assay, 
as we assumed that product inhibition will be negligible in the 
initial phase of the reaction. The initial reaction rates were plotted 
as a function of the probe concentration, followed by fitting to the 
Michaelis–Menten equation and the determination of kinetic 
parameters (KM, Vmax, and kcat; Figure 4A). The calculated KM 
values were in the micromolar range for both enzymes: 22.0 ± 2.4 
µM for Ecm1 and 11.4 ± 2.8 µM for RNMT-RAM (Table 2). Based 
on these results, we established the probe concentration at 2 µM, 
which was slightly lower than both KM values. The catalytic 
effectiveness of the enzymes (kcat/KM value)[39] was 0.075 
s−1·µM−1 for Ecm1 and 0.014 s−1·µM−1 for RNMT-RAM. The values 
suggested that probe 6b was better accepted as a substrate by 
the Ecm1 enzyme than by RNMT-RAM. 
 
Figure 4. Steady-state kinetic parameters for N7-methylation of probe 6b, 
catalyzed by Ecm1 and RNMT-RAM. A) Initial rate as a function of probe 6b 
concentration in the presence of the SAM cosubstrate and the N7-MTases: 10 
nM Ecm1/50 µM SAM or 20 nM RNMT-RAM/20 µM of SAM. B) Initial rate as a 
function of SAM cosubstrate concentrations in the presence of 2 µM of probe 
6b and the N7-MTases: Ecm1 (10 nM) and RNMT-RAM (20 nM). Data are the 
means ± SD of three independent experiments. Calculated kinetic parameters 
are shown in Table 2.  
Table 2. Steady-state kinetic parameters for Ecm1 and RNMT-RAM catalysis of N7-methylation of probe 6b. 





Enzyme KM (µM)[a] Vmax (mmol min−1 mg−1)[a] kcat (s−1)[a] kcat/KM (s−1·µM−1)[a] 
Ecm1 (20 nM) 22.0 ± 2.4 (3.13 ± 0.24) × 10−3 1.64 ± 0.13 0.074 ± 0.010 
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To set the concentration of the SAM cosubstrate, we 
investigated the saturating concentrations for Ecm1 and RNMT-
RAM N7-MTases in the presence of set concentration of probe 6b 
(Figure 4B). The final concentrations of the cofactor (SAM) used 
in the assay were then set to the values from the higher plateau. 
Finally, we established that the optimal conditions to monitor N7-
MTase activity were: 2 µM probe 6b, 50 µM SAM, and 10 nM 
Ecm1 or 2 µM probe 6b, 20 µM SAM, and 20 nM RNMT-RAM 
(Tables S2 and S3). 
For the optimized conditions, we determined z-factor values 
to validate our Ecm1 and RNMT-RAM activity assays and to 
establish their suitability for HTS experiments. To this end, we 
measured changes in FLINT at 1-minute intervals for a set of 153 
(for Ecm1) or 132 (for RNMT-RAM) positive and negative control 
samples. The positive control samples (no inhibition) consisted of 
a solution of probe 6b in the presence of SAM and an appropriate 
enzyme. The negative controls additionally contained a universal 
MTase inhibitor, sinefungin (25 µM for Ecm1 and 30 µM for 
RNMT-RAM). The z factors for both assays (0.74 for Ecm1 and 
0.67 for RNMT-RAM; Figure S5) met the criterion (z > 0.5) for an 
HTS method; hence, both assays were found to be suitable for 
the screening of compound libraries.  
Inhibition Studies 
Preliminary inhibitor screenings against Ecm1 and RNMT-RAM 
were performed using an in-house library of substrate analogs. To 
this end, a series of GpppA derivatives substituted at the C8 or 
C6 position of guanosine were synthesized (Figure S6). We 
tested C8-methyl, C8-trifluoromethyl, and C8-phenyl 
modifications, as well as a 6-S substitution of guanosine. To verify 
the effect of the second nucleotide on inhibitory properties, we 
also examined a 6-SGDP mononucleotide. 
Probe 6b (2 µM), an enzyme (10 nM Ecm1 or 20 nM RNMT-
RAM), and SAM (50 or 20 µM, respectively) were incubated with 
half-log dilutions of a potential inhibitor (0.003 nM to 100 µM), and 
the reaction progress was monitored by reading FLINT at 378 nm 
(excitation at 345 nm) at 1-minute intervals. The initial rates were 
plotted as a function of the inhibitor concentration, and the data 
were fitted to a four-parameter dose-response curve (Hill 
equation) to determine IC50 values (Figure 5, Table 3). The 
calculated IC50 values varied for Ecm1 from 15 nM to 83 µM, and 
p values (Hill slope) varied from -3.6 to -0.8 (Table 3). We found 
C8-methyl-modified GpppA to be the most potent N7-MTase 
inhibitor among the tested compounds. We also observed that 6-
SGpppA was a stronger inhibitor of Ecm1 than was 6-SGDP, which 
indicated that the presence of the second nucleotide is important 
for inhibitory properties. In general, the inhibitory potency 
decreased in the order 8-Me > 8-CF3 > 6-S > 8-Ph > unmodified, 
i.e., GpppA was the weakest of the tested inhibitors. Hence, we 
concluded that C8- and 6-S-substituted guanine nucleotides were 
a promising group of N7-MTase inhibitors.  
The determined IC50 values for the human enzyme RNMT-
RAM were 5 to 30 times higher than those for Ecm1. The only 
exception was 6-SGp3A, which was a better inhibitor for RNMT-
RAM than it was for Ecm1. This finding suggested that the 6-S 
modification was more suitable for RNMT-RAM inhibition. For 
both enzymes, sinefungin was the strongest inhibitor, with the IC50 
value of two (Ecm1) or one (RNMT-RAM) order of magnitude 
Figure 5. Inhibition of Ecm1 (A) and RNMT-RAM (B) N7-MTase activity toward 
probe 6b by selected substrate analogs and sinefungin. All reaction mixtures 
contained probe 6b (2 µM) and either SAM (50 μM), Ecm1 (10 nM) or SAM (20 
μM), RNMT-RAM (20 nM) in 50 mM Tris-HCl buffer pH 7.5. The mixtures were 
incubated at 30 ºC in a 96-well plate. The fluorescence measurements were 
carried out for excitation at 345 nm and emission at 378 nm using plate reader. 
Data are the mean ± SD of three independent experiments. The determined IC50 
and Hill slope values are shown in Table 3. 
Table 3. IC50 and p values obtained in the N7-methylation activity assay (both 
Ecm1 and RNMT-RAM) for five selected potential inhibitors and GpppA and 
sinefungin as a control[a] 
Compound 
Ecm1 RNMT-RAM 
IC50 (μM) p IC50 (μM) p 
Gp3A 32.6 ± 3.4 -1.0 ± 0.2 >100 n.d. 
8-Me-Gp3A 5.21 ± 0.68 -1.0 ± 0.1 39.3 ± 7.6 ~-2.0 
8-Ph-Gp3A 19.4 ± 3.5 -0.8 ± 0.1 >100 n.d. 
8-CF3-Gp3A 7.33 ± 0.54 -1.9 ± 0.2 104 ± 14 -1.2 ± 0.2 
6-SGDP 32.1 ± 2.1 -2.6 ± 0.6 12.0 ± 1.0 -1.7 ± 0.2. 
6-SGp3A 8.93 ± 0.81 -1.3 ± 0.1 7.55 ± 1.00 -1.5 ± 0.3 
Sinefungin 0.014 ± 0.002 -1.0 ± 0.1 0.44 ± 0.06 -1.0 ± 0.1 
[a] Data are the means ± SD of three independent experiments. 
lower than that for the best nucleotide inhibitor (8-Me-GpppA or 6-
SGpppA, respectively). However, sinefungin, as a SAM analog, is 
not a selective inhibitor and can influence a number of different 
MTases. Properly designed nucleotide compounds with a 
substrate-like structure have a better chance to selectively inhibit 
N7-MTases only. Therefore, further exploration of nucleotide 
modifications could be beneficial for drug design. 
We next used our method to screen a commercially available 
library of pharmacologically active compounds (LOPAC®1280) 
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conditions, i.e., 2 µM probe 6b, 50 µM SAM, and 10 nM Ecm1 in 
50 mM Tris-HCl, pH 7.5. The compounds were screened at 10 
µM. The experiments were carried out in a 96-well plate format, 
wherein each plate contained 80 test compounds and 16 control 
wells. Fourteen of the 1,280 test compounds showed interference 
with Py fluorescence and had to be tested on a separate plate. 
Relative reaction progress values were calculated by normalizing 
the initial rate to the maximum initial rate, without an inhibitor 
(Figure 6A). The candidate selection cutoff was set at 10% of the 
maximum reaction rate, leading to the identification of 56 potential  
 
Figure 6. A) Relative reaction progress of Ecm1-catalyzed N7-methylation of 
probe 6b in the presence of 1,280 compounds from the LOPAC®1280 library. Data 
are the means ± SD of two independent experiments. B) IC50 values of selected 
compounds against Ecm1 N7-MTase activity for 6b (relative reaction progress 
≤10%) and sinefungin as a control. Data are the means ± SD of two or three 
independent experiments. The determined IC50 values are shown in Table S4. 
Table 4. IC50 values obtained in the N7-methylation activity assay (Ecm1, 
RNMT-RAM, and VCE) for eight selected potential inhibitors and sinefungin as 
a control. [a] 
Compound 
IC50 (μM) 
RNMT-RAM Ecm1 VCE 
Aurintricarboxylic 
acid 
0.47 ± 0.01 0.031 ± 0.005 n.d. 
NF 023 1.80 ± 0.33 0.015 ± 0.005 n.d. 
Reactive blue 2 3.30 ± 0.73 0.043 ± 0.007 n.d. 
Suramin 0.70 ± 0.08 0.046 ± 0.006 0.083 ± 0.015 
Galloflavin n.d. 0.12 ± 0.02 n.d. 
Quercetin n.d. 0.12 ± 0.02 n.d. 
Myricetin n.d. 0.14 ± 0.01 n.d. 
8-Me-Gp3A 39.3 ± 7.6 5.21 ± 0.68 31.0 ± 6.8 
Sinefungin 0.53 ± 0.07 0.014 ± 0.002 0.078 ± 0.026 
[a] Data are the means ± SD of two or three independent experiments. 
hits. The hits were further evaluated for their IC50 values (Figure 
6B, Table 4, Table S4). Consequently, 14 compounds showed 
IC50 values below 400 nM, of which four compounds had IC50 
values < 50 nM. The most potent inhibitor was a suramin analog, 
NF 023, with an IC50 value of 15 nM, which was similar to that of 
sinefungin (14 nM). The other three most potent inhibitors were 
aurintricarboxylic acid (AA), reactive blue 2, and suramin (Figure 
7A, Table 4). Another group of identified N7-MTase inhibitors 
included three small molecules consisting of aromatic rings 
modified with hydroxyl groups, namely, galloflavin (IC50 = 120 ± 
20 nM), quercetin (IC50 = 120 ± 20 nM), and myricetin (IC50 = 140 
± 10 nM). Using RP-HPLC analysis, we independently confirmed 
that each of these compounds inhibited the N7-methylation 
process (Figures S7 and S8). 
Selected Ecm1 inhibitors from the LOPAC®1280 library were 
next tested against RNMT-RAM (Figure 7B, Table 4). The IC50 
values for RNMT-RAM were approximately one order of 
magnitude lower than those for Ecm1, similar to the previous 
results for the GpppA-based inhibitors. Finally, the same 
methodology was used to evaluate selected compounds with 
VCE (Figure S9). In this case, IC50 values were determined for 
three inhibitors identified in studies with the two other enzymes, 
suramin from the LOPAC®1280 library, 8-Me-GpppA from the 
substrate minilibrary, and sinefungin. The experiment was carried 
out as previously for Ecm1, with 2 µM probe 6b, 50 µM SAM, and 
5U of VCE incubated with half-log dilutions of the inhibitors 
(Figure S10). We found no direct correlation between the IC50 
values determined for VCE and Ecm1. After normalizing the IC50 
values of the most potent inhibitors to the values of sinefungin for 
all three N7-MTases, we concluded that while NF 023 was the 
best Ecm1 inhibitor, aurintricarboxylic acid and suramin were the 
most potent ones for RNMT-RAM (Figure S11). The IC50 values 
of suramin and sinefungin were similar (0.083 µM and 0.078 µM) 
for the VCE enzyme. However, the lack of differences between 
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 Figure 7. Inhibition of N7-MTase activities of A) Ecm1 and B) RNMT-RAM 
toward 6b by the most potent selected substrate analogs and sinefungin. All 
reaction mixtures contained probe 6b (2 µM) and either SAM (50 μM), Ecm1 
(10 nM) or SAM (20 μM), RNMT-RAM (20 nM) in 50 mMTris-HCl buffer pH 7.5. 
The mixtures were incubated at 30 ºC in a 96-well plate reader. The 
fluorescence measurements were carried out for excitation at 345 nm and 
emission at 378 nm. Data are the means ± SD of two or three independent 
experiments. The determined IC50 and Hill slope values are shown in Table 4. 
Discussion 
In this study, we sought to develop a straightforward and cost-
effective method for direct monitoring of mRNA cap N7-MTase 
activity based on changes in FLINT and adaptable to high-
throughput inhibitor screening. As a model of a well-characterized 
MTase, we selected Ecm1 from E. cuniculi. The conditions 
optimized for Ecm1 were subsequently successfully applied to 
human RNMT in a complex with RAM and to the viral protein VCE.  
Among various fluorescent probes derived from the GpppA 
dinucleotide, only a Py3-labeled compound was found to be 
suitable as a FLINT probe. This finding is consistent with our 
previous observations on 7-methylguanosine mononucleotides, 
which revealed that Py was a unique fluorophore, with 
fluorescence properties variably amenable to quenching by 
different nucleobases.[40] Further detailed structural optimization 
led to the selection of probe 6b as an MTase substrate with 
fluorescent properties that were most sensitive to the N7-
methylation status. Ecm1 and RNMT-RAM fluorescent assays 
were developed and validated by determining their z-factors. Both 
assays were found to be suitable for HTS experiments, as their z-
factor values exceeded 0.5 (0.74 for Ecm1 and 0.67 for RNMT-
RAM).  
These assays were used to screen a small collection of six 
nucleotides substituted at the C8 or C6 position, which led to the 
identification of several moderately potent compounds, including 
8-Me-GpppA as the most potent inhibitor of Ecm1 and 6-SGpppA 
as the most potent inhibitor of RNMT-RAM. These results suggest 
a possibility of selective targeting of N7-MTases from different 
sources with substrate-derived inhibitors.  
We finally applied our method to high-throughput screening of 
a commercially available library consisting of 1,280 drug-like 
molecules against the Ecm1 MTase. Consequently, 56 hits were 
identified, which showed at least 90% inhibition of the reaction. 
Further evaluation of these 56 compounds identified a suramin 
analog, NF 023, as the most potent inhibitor, with the potency 
similar to that of sinefungin under assay conditions. Suramin was 
also a strong N7-MTase inhibitor, albeit weaker than NF 023 was. 
Suramin and suramin analogs act on multiple biological targets,[41] 
often interacting with nucleotide-binding sites of targeted 
proteins.[42] In particular, histone MTases have been identified 
among suramin-sensitive enzymes.[43] AA was also confirmed as 
an N7-MTase inhibitor. This compound polymerizes in aqueous 
solutions, which results in unspecific inhibition of protein–nucleic 
acid interactions.[44] AA has already been found to inhibit an N7-
MTase from CoV[32] via interaction with the 3′-OH group in the 
protein-bound SAM.[45] Similar to suramin, AA affects many 
molecular targets, thus showing reduced selectivity. Other 
identified inhibitors included the flavonoids galloflavin, quercetin, 
and myricetin, which appear to be promising for further structure 
optimization, owing to their relatively low molecular weights. 
Quercetin and myricetin have already been found to inhibit activity 
of SARS-nsp14 N7-guaninmethyltransferase, and human RNMT-
RAM enzymes.[35] An interesting finding was that reactive blue 2 
also potently inhibited N7-MTases. Based on the comparison of 
our hits with structurally similar library compounds with lower or 
no activity, we conclude that the presence of sulfonic groups 
tends to increase the inhibitory potential. Naphthyl-sulfo groups of 
suramin have been found to compete with peptides in the N7-
arginine MTase reaction catalyzed by the PRTM1 enzyme.[46] An 
anionic sulfonate substituent forms hydrogen bonds with 
guanidinonitrogens, and the naphthalene ring interacts with the 
arginine side chain through van der Waals interactions and π-
stacking.[46] Some other interesting hits that were identified 
included tyrphostin 51, mifamurtide, protoporphyrin IX, 6-hydroxy-
DL-DOPA, cefsulodin, and Ro 8-4304. To the best of our 
knowledge, their inhibitory properties for mRNA cap N7-MTases 
are reported here for the first time. The most potent inhibitors 
selected by our fluorescence assay should be further evaluated 
in studies on mRNA 5’ cap biosynthesis using short and long 
GpppRNA substrates 
Conclusion 
In conclusion, we report a direct assay for real-time monitoring of 
the activities of mRNA cap N7-MTases and their inhibition. The 
method is based on changes in FLINT of a synthetically available 
Py-labeled GpppA analog (probe 6b) and does not require 
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assay was found to be applicable to N7-MTases from different 
sources and was successfully implemented for N7-MTase 
inhibitor discovery. Limitations of the assay include potential 
interferences from compounds with emissive properties similar to 
those of Py (UV and near Vis range) and a relatively high probe 
concentration (low micromolar range) required for the optimal 
kinetics. Nevertheless, our method was suitable for determining 
IC50 parameters of all interfering compounds from LOPAC®1280. 
Experimental Section 
All experimental details can be found in the Supporting 
Information.  
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The m7G cap biosynthesis is an important step of mRNA maturation, involving mRNA cap guanine-N7 methyltransferase, which is a 
potential target for antiviral and anticancer therapies. This is the first report of a direct HTS, fluorescence-based method for monitoring 
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